我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
8
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
5
62.5%
终止
2
25.0%
撤回
1
12.5%
暂无批准数据
- Novoxel Inc. and GPOphtho have finalized a strategic agreement to expand access to the Tixel device family for treating dry eye and aesthetic procedures nationwide. - The Tixel i device specifically targets Meibomian Gland Dysfunction (MGD) with a 2-minute treatment for both eyes, supported by recent clinical trial data showing safety and efficacy. - The FDA-cleared device uses proprietary Thermo-Mechanical Action technology to provide non-invasive treatments without needles, bleeding, or radiation exposure. - The partnership enables eyecare physicians to integrate both functional dry eye treatments and cosmetic procedures, creating new revenue streams through discounted pricing packages.
